

# Yu-Yun Shao

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1117279/yu-yun-shao-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

1,549  
citations

23  
h-index

34  
g-index

123  
ext. papers

1,899  
ext. citations

4.5  
avg, IF

4.51  
L-index

#	Paper	IF	Citations
97	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.. <i>BMC Cancer</i> , <b>2022</b> , 22, 55	4.8	2
96	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
95	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 1581-1590	3.2	0
94	An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , <b>2021</b> , 26, 422-426	5.7	0
93	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	1
92	Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 559-566	3.2	4
91	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 1-4	3.2	2
90	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 1051-1060	3.2	18
89	Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 781-782	3.2	1
88	Solving the deficit of cancer pain management skills by education programs. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 1843-1848	3.9	2
87	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , <b>2021</b> , 84, 144-150	2.8	1
86	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 809-822	5.3	2
85	Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan. <i>The Lancet Regional Health - Western Pacific</i> , <b>2021</b> , 16, 100255	5	1
84	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. <i>Oncologist</i> , <b>2020</b> , 25, e1280-e1285	5.7	6
83	Satisfaction with pain management and impact of pain on quality of life in cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, e91-e98	1.9	6
82	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	9
81	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 615-621	4.2	3

80	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. <i>Liver Cancer</i> , <b>2019</b> , 8, 110-120	9.1	27
79	Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 1663-1672	3.9	5
78	Early alpha-fetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. <i>Liver International</i> , <b>2019</b> , 39, 2184-2189	7.9	27
77	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2019</b> , 8, 480-490	9.1	28
76	Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , <b>2019</b> , 39, 5675-5682	2.3	16
75	Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management. <i>Journal of Opioid Management</i> , <b>2019</b> , 15, 147-158	0.8	1
74	A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 2857-2867	3.9	10
73	Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. <i>Analytica Chimica Acta</i> , <b>2018</b> , 1019, 93-102	6.6	28
72	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. <i>Anticancer Research</i> , <b>2018</b> , 38, 4805-4812	2.3	3
71	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure. <i>Liver Cancer</i> , <b>2018</b> , 7, 205-208	9.1	2
70	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 421-429	3.5	15
69	National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients. <i>Oncologist</i> , <b>2017</b> , 22, 843-849	5.7	12
68	Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan. <i>Journal of Pain and Symptom Management</i> , <b>2017</b> , 54, 55-65.e1	4.8	11
67	Right or left? Side selection for a totally implantable vascular access device: a randomised observational study. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 932-937	8.7	8
66	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 722-730	6.1	7
65	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 533-539	3.9	7
64	High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , <b>2017</b> , 47, 949-953	2.8	27
63	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15656-e15656	2.2	1

62	Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. <i>Oncotarget</i> , <b>2017</b> , 8, 86681-86692	3.3	7
61	Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. <i>Anticancer Research</i> , <b>2017</b> , 37, 2593-2599	2.3	14
60	Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study. <i>Anticancer Research</i> , <b>2017</b> , 37, 7095-7104	2.3	4
59	Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 624-624	2.2	
58	Key opioid prescription concerns in cancer patients: A nationwide study. <i>Acta Anaesthesiologica Taiwanica</i> , <b>2016</b> , 54, 51-6		7
57	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1336-41	4	21
56	Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2555-64	12.9	28
55	Effect of national policy changes on hospice utilization and the invasiveness of end-of-life care in cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10008-10008	2.2	1
54	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. <i>Journal of Cancer</i> , <b>2016</b> , 7, 1515-23	4.5	5
53	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. <i>BMC Cancer</i> , <b>2016</b> , 16, 327	4.8	32
52	Inhibition of the Wnt/ $\beta$ -catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. <i>Cancer Letters</i> , <b>2016</b> , 381, 58-66	9.9	31
51	Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials. <i>Oncology</i> , <b>2015</b> , 88, 345-52	3.6	21
50	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 177-184.e4	3.8	27
49	Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer. <i>Molecular and Cellular Proteomics</i> , <b>2015</b> , 14, 1527-45	7.6	46
48	Young patients with colorectal cancer have increased risk of second primary cancers. <i>Japanese Journal of Clinical Oncology</i> , <b>2015</b> , 45, 1029-35	2.8	8
47	The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. <i>Oncologist</i> , <b>2015</b> , 20, 1051-7	5.7	9
46	High Serum Transforming Growth Factor- $\beta$ Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3678-84	12.9	66
45	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 137-43	4.9	8

44	Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 10336-47	5.6	29
43	Tumor c-Met expression and prognosis of advanced hepatocellular carcinoma patients treated with sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 317-317	2.2	
42	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 313-8	13.4	36
41	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. <i>Journal of Hepatocellular Carcinoma</i> , <b>2014</b> , 1, 85-99	5.3	15
40	Type 2 diabetes mellitus is associated with increased mortality in Chinese patients receiving curative surgery for colon cancer. <i>Oncologist</i> , <b>2014</b> , 19, 951-8	5.7	19
39	Ectenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma. <i>Oncology</i> , <b>2014</b> , 87, 159-66	3.6	21
38	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases. <i>Journal of the Formosan Medical Association</i> , <b>2014</b> , 113, 577-8	3.2	3
37	Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4100-4100	2.2	
36	Risk of second primary malignancies in young patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14533-e14533	2.2	
35	The impact of diabetes mellitus on early cervical cancer in Bia: A population-based cohort study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e16501-e16501	2.2	
34	Clinical Activity of Metronomic Chemotherapy in Liver Cancers <b>2014</b> , 189-202		
33	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy. <i>Anticancer Research</i> , <b>2014</b> , 34, 1047-52	2.3	8
32	Clinical trials in hepatocellular carcinoma: an update. <i>Liver Cancer</i> , <b>2013</b> , 2, 345-64	9.1	54
31	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 106-14	7.5	19
30	Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?. <i>Liver Cancer</i> , <b>2013</b> , 2, 93-107	9.1	30
29	Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases. <i>International Journal of Hepatology</i> , <b>2013</b> , 2013, 141590	2.7	4
28	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. <i>Liver International</i> , <b>2013</b> , 33, 1413-9	7.9	11
27	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. <i>Cancer</i> , <b>2013</b> , 119, 1210-6	6.4	11

26	Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. <i>Oncology</i> , <b>2013</b> , 85, 44-52	3.6	43
25	The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma. <i>Oncology</i> , <b>2013</b> , 85, 312-6	3.6	6
24	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. <i>PLoS ONE</i> , <b>2013</b> , 8, e80276	3.7	22
23	Unique histopathologic features of brain metastases from hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 169-169	2.2	
22	Association of diabetes mellitus with increased mortality in patients receiving curative surgery for colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 399-399	2.2	2
21	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. <i>Oncology</i> , <b>2012</b> , 82, 59-66	3.6	28
20	Survival following surgery with or without adjuvant chemotherapy for stage I-IIIa non-small cell lung cancer: an east asian population-based study. <i>Oncologist</i> , <b>2012</b> , 17, 1294-302	5.7	10
19	The impact of diabetes mellitus on prognosis of early breast cancer in Asia. <i>Oncologist</i> , <b>2012</b> , 17, 485-91	5.7	35
18	Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3992-7	12.9	37
17	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1672-7	8.7	18
16	Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. <i>Oncologist</i> , <b>2012</b> , 17, 856-62	5.7	29
15	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. <i>Oncologist</i> , <b>2012</b> , 17, 970-7	5.7	9
14	Survival of patients with small cell lung carcinoma in Taiwan. <i>Oncology</i> , <b>2012</b> , 82, 19-24	3.6	21
13	Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma. <i>Anticancer Research</i> , <b>2012</b> , 32, 4865-70	2.3	10
12	Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. <i>Oncologist</i> , <b>2011</b> , 16, 82-6	5.7	27
11	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. <i>Oncology</i> , <b>2011</b> , 81, 98-103	3.6	15
10	Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. <i>Anticancer Research</i> , <b>2011</b> , 31, 4007-11	2.3	8
9	Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2010</b> , 6, 80-8	1.9	23

8	Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. <i>Japanese Journal of Clinical Oncology</i> , <b>2010</b> , 40, 286-93	2.8	21
7	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 126-31	13.4	107
6	Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. <i>Journal of the Formosan Medical Association</i> , <b>2010</b> , 109, 362-8	3.2	22
5	Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2010</b> , 46, 694-7	4.4	5
4	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , <b>2010</b> , 116, 4590-6	6.4	129
3	Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. <i>Discovery Medicine</i> , <b>2010</b> , 9, 538-45	2.5	9
2	Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment. <i>Anticancer Research</i> , <b>2009</b> , 29, 1665-7	2.3	1
1	Fatal thrombocytopenia after oxaliplatin-based chemotherapy. <i>Anticancer Research</i> , <b>2008</b> , 28, 3115-7	2.3	20